Research from LSU Health Shreveport has shown that nitric oxide is a strong protector against tissue hypoxia. “It’s just really a raging phenomenon that occurs in the lung and if we can just calm that down a little bit and allow the body’s natural systems to come in an heal it, that’s the real goal,” said Scott.
The School of Graduate Studies helps to train future scientists and our Centers further elevate our institution's research portfolio. The Office of Research helps support these endeavors and is comprised of the Clinical Trials Office, the Office of Sponsored Programs and Technology Transfer, Human Research Protections Program (HRPP) and the Institutional Review Board (IRB).
Research funding continues to grow on our campus with well over $10 million in the last fiscal year. Videos below outline the new patents, grants and clinical trials taking place on our campus.
The plasma transfusion is a clinical trial to see whether anitbodies that their immune systems created would help those who are battling a more advanced stage of the coronavirus. The trial is the first of its kind in Louisiana and the third of its kind in the U.S.
Dr. Martin Sapp, Chair of Microbiology at LSUHS, shares how the EVT Lab will help with current and future viral threats.
The Shreveport Times reached out to Professor Andrew Yurochko, Carroll Feist endowed chair of viral oncology and department vice-chair of microbiology and immunology, LSUHS, with the Emerging Viral Threat lab which began processing COVID-19 samples last Wednesday.
LSU Health Shreveport has established the Emerging Viral Threat (EVT) Laboratory to address the need for faster detection and processing of COVID-19 tests.
Having an academic medical center is a “gem” touted frequently throughout north Louisiana and beyond. While many in the nation are fearful of having appropriate access to testing and quality care during the Covid-19 pandemic, thanks to LSU Health Shreveport, north Louisiana is infinitely better positioned than most communities to face Covid-19.
LSUHS leadership, faculty, staff, students and community supporters recently honored the continued growth of research initiatives and funding at the second annual Research Celebration event held on February 25, 2020.
Cherie-Ann O. Nathan, MD is the lead author of a study that found a targeted therapy drug used for breast and kidney cancers may also extend survival for patients with advanced head and neck cancer.
Internationally recognized for his research on inflammatory vascular pathology, specifically on and the relationship between inflammation and vascular growth and function, Dr. Kevil discovered detailed mechanistic relationships between angiogenesis and inflammation.
The Science & Medicine Academic Research Training Program provides academically advanced high school seniors who are interested in careers related to medicine, scientific research, and biomedical engineering opportunities to engage in intensive research with medical clinicians, researchers, and academic staff.